Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development

By sjmartinez • August 22, 2024

Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, Wang S, Yin J, Ding L, Ran X, Fan S, Sun Q, Tan SY, Koeffler HP, Li J, Mi Y, Chen YQ. Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development. Int J Biol Macromol. 2024 Aug 19:134844. doi: 10.1016/j.ijbiomac.2024.134844. Epub ahead of print. PMID: 39168191.

Tags: castration-resistant prostate cancer, Drug-tolerant persister, Hematology/Oncology, Nuclear factor erythroid 2-related factor 2, peroxiredoxin 5, Publications, stachyose, Stachyose caproate

Related Posts

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

Rodon J, O'Neil B, Lim C, Ammakkanavar NR, Torrado C, Matsuoka K, Hirai H, Miura A, Anderson B, Jin L, Hangai N, Long A, Wacheck[...]

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming[...]

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer

Swisher EM, Konecny G, Cohen J, Colon-Otero G, Danziger N, Lin DI, Li G, Quintanilha JCF, Decker B, Ross JS, Gearing M, Baker K, Scott[...]